Gilead — Pivotal Covid-19 study of remdesivir ‘met its primary endpoint,' is emergency authorization next?
Gilead has declared a huge victory in the war against Covid-19.
In a short statement, the big biotech said that the pivotal, controlled study of remdesivir at the National Institute of Allergy and Infectious Diseases had met its primary endpoint. This was one of the key clinical hurdles set up by NIAID chief Anthony Fauci.
Gilead $GILD included no data in their statement, but said that NIAID is planning to sketch out the positive results in an upcoming briefing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,100+ biopharma pros reading Endpoints daily — and it's free.